Making Healthcare More Accessible

Unlock the potential of Asia with Zuellig Pharma's unique healthcare solutions.

Select Market

Australia
Brunei
Cambodia
China
Hong Kong - Macau
India
Japan
Korea
Malaysia
Philippines
Singapore
Taiwan
Thailand
Vietnam
Indonesia

Zuellig Pharma's depot in South Australia is a TGA-licensed facility that is approximately 1,300 sq.m. The facility has managed over 1,000 clinical trials since its foundation and currently manages more than 350 clinical trials.

Zuellig Pharma's Cambodia facilities offer a newly-built distribution centre with an over 6,300 sq.m. warehouse and 1,200 sq.m. mezzanine for healthcare products, including 6,400 pallets in 6-high racking and 240 cold room storage pallets. With 90% coverage of ethical, pharmacy, and modern trade, we serve over 10,000 healthcare customers nationwide, including hospitals, clinics, and pharmacies, through 200 sales and marketing representatives. Our quality of work is recognised with certifications such as GDSP, GMP, GDPMDD, and ISO 9001:2015.

Zuellig Pharma China's Beijing facility, with 20 years of clinical supply experience, is GDP/GMP compliant and a trusted partner for various clients in clinical trials, including pharmaceutical companies, CROs, CMOs, biopharmaceutical firms, medical device companies, and diagnostic firms.

Zuellig Pharma has two warehouses in Hong Kong spanning over 48,000 sq.m., offering air-conditioned storage for 24,000 pallets and cold chain storage for 800 pallets. We serve 10,000+ healthcare customers, including hospitals, clinics, dentists, and drug stores. Zuellig Pharma moves 48,000 cubic meters of products annually and has won awards such as the HR Distinction Awards - Excellence in Employee Wellbeing and Occupational Health Award - Excellence Award of Joyful@Healthy Workplace Best Practices Award.

Zuellig Pharma's facility in India is strategically-located in Mumbai to ensure that products and services are made available with the shortest leadtime. Covering over 1,530 sq.m., the facility offers one-stop solutions for every client's clinical trial needs, including a global depot and cold chain logistics network with temperature-controlled infrastructure and GDSP and GMP facilities for fast product and service availability. India is a cost-efficient and profitable market for major pharma, and biotech companies, as well as CROs, with local models meeting country standards.

Zuellig Pharma has an impressive partner depot facility in Japan, covering a total area of around 1.2 million sq.m., out of which 300,000 sq.m. are solely dedicated to pharmaceutical handling. Apart from its extensive size and specialisation, the partner depot also prioritises sustainability, evident through the installation of solar power generation systems and nighttime heat storage type air conditioning systems in all its offices.

Zuellig Pharma's Korea facilities comprise 12 warehouses and a team of 150 sales and marketing representatives serving over 36,000 healthcare customers nationwide. We have received various accolades and certifications for sustainability, transparency in pharmaceutical distribution, and industry leadership.

Zuellig Pharma's Malaysia facilities include a main warehouse in Bukit Jelutong and an approximately 7,000 sq.m. warehouse for dialysis solutions, medical supplies, and surgical lenses. With two branch offices and a branch warehouse, Zuellig Pharma has 100% coverage of hospitals, clinics, and pharmacies with over 15,000 customers across Malaysia. We have won numerous awards for quality and certifications.

Zuellig Pharma in the Philippines has seven distribution warehouses covering over 59,000 sq.m. of distribution centre space for pharma, consumer, medical devices, and diagnostics products. We have over 1,700 employees nationwide and have distributed to over 19,000 physicians, 700 private hospitals, 7,000 chain drug stores, and more. We have been recognised for our quality of work and sustainability efforts.

Zuellig Pharma's Singapore facilities cover over 44,000 sq.m. across three warehouses and serve over 6,000 healthcare customers with extensive ethical, pharmacy, and modern trade coverage. We have received various accolades and certifications, such as the HR Asia Best Companies to Work (2020) for Singapore, IDC Future Enterprise Awards (2022), and National Awards (COVID-19) 2022 recipient for President's Certificate of Commendation for Singapore.

Zuellig Pharma in Taiwan boasts five warehouses spanning over 65, 000 sq.m. and catering to pharmaceuticals, consumer goods, and medical devices. We offer 100% coverage of ethical, pharmacy, and modern trade services, serving 20,000+ healthcare customers with over 200 sales and marketing representatives. We have received accolades like the National Healthcare Quality Award and National Biotechnology and Medicine Care Quality Award.

Zuellig Pharma runs four warehouses in Thailand, with 56,400 pallet storage space and a full range of temperature-controlled cold chain rooms for various products. We offer 98% customer coverage of ethical, pharmacy, and OTC, serving over 22,000 healthcare customers with 500 sales and marketing representatives, and have distributed 87% of vaccines to date. We have received numerous accolades, including nine awards at the 2022 TCCTA Contact Center Awards.

Zuellig Pharma's Vietnam facilities comprise five warehouses with over 23,000 AC pallets and 1,700 CC pallets, catering to various healthcare products. We provide 100% coverage across all medical channels, serving over 60,000 healthcare customers. Our certifications include GDP, GCP, GMP, GSP and GSDP, GDPMD, ISMS, and ISO.

Zuellig Pharma provides complete coverage of ethical, pharmacy, and modern trade products in Indonesia, serving over 26,000 direct outlets with over 2,800 trained employees, 25 warehouses, 4 sales offices, and 8 APL partners' locations. The team has amassed numerous accolades, such as the HR Asia Best Companies to Work for in Asia and CNBC Indonesia Outstanding Company in Sustainability-Community Initiative awards.

Solutions

View All

At Zuellig Pharma, we bridge the gap between clients and customers in the healthcare value chain by providing customised and innovative healthcare solutions that ensure unbeatable access to care throughout Asia.

Distribution
ZP Therapeutics
Clinical & Reach
Technology Solutions
Patient Solutions

State-of-the-art end-to-end distribution solutions across 13 markets

Distribution

Experience unparalleled access to the healthcare market with Zuellig Pharma. Our comprehensive range of pharmaceutical distribution services and tailored healthcare solutions empower your business to reach its full potential. As a trusted leader in the industry, Zuellig Pharma delivers custom healthcare solutions that meet your unique needs.

Discover More

Understands consumers, customers and market in Asia

ZP Therapeutics

Zuellig Pharma is your trusted commercialisation partner in the healthcare industry. We specialize in delivering innovative pharma solutions to enhance patient access to care. Our flexible partnership models cater to diverse client needs. With extensive expertise in Asia, we provide regulatory and governmental affairs support, along with sales and marketing strategies to help businesses expand their reach and impact.

Discover More

The future of clinical trials is brighter than ever.

Clinical Reach Title

Partner with Zuellig Pharma for seamless management of clinical trial supply chains. From regional studies to complex global multi-center trials, our expertise spans diverse scales. With our global product sourcing, integrated storage and pharmaceutical distribution solutions, and localized returns management, we ensure compliance with local and international healthcare regulations for your clinical needs.

Discover More

Your digital platform of choice

Technology Solutions

Revolutionise Asia's healthcare ecosystem with Zuellig Pharma's innovative pharmaceutical software platforms. Our advanced solutions bridge the gaps, enhancing access and outcomes for clients, healthcare professionals, and patients. With cutting-edge technology, businesses can streamline operations, expand their reach, and deliver the care patients deserve.

Discover More

Personalised and innovative healthcare support

Patient Solutions

Experience patient-centric care with Zuellig Pharma's Patient Solutions platform. Our personalised healthcare solutions and support empower patients to take control of their well-being. With innovative features like mobile apps, home care services, and disease management programs, we enhance the patient experience and improve health outcomes.

Discover More

Segments

Long and lasting relationships with leading healthcare pharmaceutical companies across multiple industry verticals.

Technology Solutions

View All

Digital technologies are at the core of our services. Learn how governments and partner companies are driving efficiency and effectiveness with Zuellig Pharma.

eZTracker

eZTracker by Zuellig Pharma is an advanced supply chain management solution that helps businesses track and monitor their healthcare products in real-time.

Visit eZTracker

eZRx

eZRx by Zuellig Pharma is a cutting-edge platform that streamlines pharmaceutical ordering and delivery processes. eZRx enables seamless communication between healthcare professionals and suppliers for efficient & effective medication management.

Visit eZRx

About Us

We provide world-class distribution, technology, commercial, and integrated health solutions and services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multi-billion dollar business covering 16 markets with over 12,000 employees.

Learn about Zuellig Pharma

Sustainability

At Zuellig Pharma, we prioritise sustainability for a healthier future through ethical business practices, resource conservation, and community support. Our EcoVadis Platinum Rating for 2023 showcases our dedication to pursuing a better tomorrow for our generation and beyond.

See Our Impact

News and Insights

View All

Discover what Zuellig Pharma is doing across the globe.

BA TEST 18 MARCH

<picture data-fileentryid="2253661"><img alt="" data-fileentryid="2253661" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/All-aboard-the-cold-chain/all_aboard_the_cold_chain.png" style="margin-right: auto; margin-left: auto;" /></picture> The global cold chain market is poised to grow around 7.8% over the next decade to reach approximately US$339.15 billion by 2025. One of the biggest driving forces behind this growth is the rising demand for pharmaceuticals that require temperature-control infrastructure and technologies. “Currently, more than 80% of the world’s pharmaceutical products require some form of temperature management to ensure product quality and efficacy is maintained, and this requirement will continue to grow with the expanding range of biopharma products entering the supply chain,” said Zuellig Pharma Corporate Head of Quality Assurance, Brett Marshall. The efficacy of today’s higher value and structurally complex drugs can be destroyed through a single cold chain break, the integrity of controlled room temperature products can be impacted through inconsistent environmental conditions during distribution, while a weak link in the management of temperature sensitive clinical trial materials can impact study outcomes and lead to extremely costly delays in bringing new products to market. These challenges, along with the globalization of supply chains and increased regulatory requirements, makes temperature management throughout the pharmaceutical industry a difficult but urgent matter to manage. Changing market needs One of the most significant changes within the pharmaceutical industry in recent years is the evolution of drug portfolios. Many manufacturers are moving away from chemical pharmaceuticals towards more structurally complex biotechnology drugs. Biologics accounted for 29% of branded global pharmaceutical sales in 2014, while specialty drugs accounted for one-third of total drug costs in 2016 with expected growth to 50% in 2020. Biologic pharmaceutical products have much stricter handling requirements and failure to adhere to these requirements at any point in the drug’s lifecycle can impact product quality and efficacy, put patients at risk or result in significant product waste and supply chain disruption. Vaccines are one of the most common type of biologic drug that requires handling at temperatures between 2°C - 8°C to maintain its efficacy and safety. Any break in this cold chain, from production, to storage, transportation, or usage could damage the integrity of the vaccine, resulting in reduced efficacy and safety in treatment. According to the World Health Organization, more than 50% of all vaccines manufactured in the world each year are destroyed during the storage and delivery process. To cope with this problem, the pharmaceutical industry has been investing in new solutions to mitigate the risk of temperature excursions. Zuellig Pharma’s eZCooler packaging system is one example of this. The eZCooler extends the holding time of temperature sensitive products to five days, versus two days with traditional systems ensuring the integrity of products to the last mile of distribution. In the hot, often temperamental climates in Southeast Asia, this system has a big role to play in helping to ensure temperature-sensitive products reach their destination in good condition, particularly in remote, rural areas. Clinical trial management These changing needs impact the storage and distribution of finished products and impact clinical trial logistics. Biologic drugs are more sensitive to the external environment, requiring cold chain handling and more regulatory approvals during the clinical trial process. This can add significant cost to the trial and lead to study and drug approval delays. Waste due to temperature excursions can therefore easily lead to stock-outs of required products, an inability to supply enrolled patients or re-supply issues for patients already under treatment in a randomized study. This could delay studies, pushing back the introduction of a new treatment or drug for patients and costing the trial sponsor millions of dollars in R&D costs as well as potential sales. Compliance Regulators are placing a much higher level of scrutiny on quality systems and processes and temperature management is one key element of this. Regulatory bodies require proof that all drugs and biological components have been distributed within the required temperature range – meaning all processes and sub processes need to be validated to ensure there has been no negative impact on the safety, efficacy or quality of a product. To do this, monitoring and reporting technology such as temperature monitors, sensors and track and trace systems are used. Much of this reporting is currently provided on a historical basis, at the end of a journey or delivery, but there is a growing trend towards real time monitoring which will provide alerts if the temperature deviates beyond the safe range. Companies need to invest in more sophisticated supply chain infrastructure to comply with new regulations and while this can be costly, the cost of non-compliance is likely to be much higher. A single consignment of drugs being distributed can be worth millions of dollars and a cold chain break can mean an entire shipment needs to be written off while a recalled batch of drugs due to temperature excursion can lead to significant reputational damage or regulatory scrutiny. How we help Zuellig Pharma takes quality very seriously. All our warehouses are Good Storage and Distribution Practice (GSDP) and Good Distribution Practice (GDP) certified with annual audits to help us stay on top of quality management standards and develop more efficient processes. Our Specialty Solutions Group maintains a network of 14 clinical trial depots across Asia, offering integrated storage, distribution, returns and destruction, re-labelling and a comparator drug-sourcing service. Having supported over 1,800 clinical trials, our network of local and central depots have the knowledge and experience to provide a one stop shop clinical trial support. This enables sponsors to customise their clinical supply chain set-up for each study, taking into account regulatory considerations, risk aspects, required shipment turnaround times, and geographical focus, with the aim of balancing study objectives against cost. We have shared our cold chain practices with governments around the region. In late 2017, we partnered with two departments under the Ministry of Health in Vietnam to support them in strengthening their cold chain capabilities nationwide. This involves working on a two-year programme with the National Centre for Control of Vaccines and Biologicals and the National Institute of Hygiene and Epidemiology, to enhance cold chain storage management and train more people in the careful handling of vaccines during distribution across Vietnam.

Zuellig Pharma wins four awards at the Asia corporate excellence & sustainability awards 2021

Zuellig Pharma, a leading healthcare services provider in Asia, has been presented with four leadership and sustainability awards, in both individual and enterprise categories, at the recent Asia Corporate Excellence and Sustainability (ACES) Awards. Organised by <a href="http://www.morsgroup.com/" target="_blank" rel="noopener noreferrer">MORS Group</a>, the annual ACES Awards is a prestigious accolade that recognises inspiring leaders, sustainability advocates as well as businesses' contributions to their communities and the world. The four titles achieved include 'Top Sustainability Advocates in Asia' by Zuellig Pharma's Regional Office, 'Industry Champions of the Year' by Zuellig Pharma Singapore, 'Community Initiative' by PT Anugerah Pharmindo Lestari (APL), Zuellig Pharma's subsidiary in Indonesia, and 'Outstanding Leaders in Asia' under the Individual awards category by APL's President Director Christophe Piganiol. Zuellig Pharma's Regional Office was recognised for integrating various CSR initiatives into its policies and operations, having a high level of employees and top management involvement in the programmes and having a genuine interest in the wellbeing of all of its stakeholders. Zuellig Pharma Singapore was awarded for its leadership in the healthcare space displayed through commendable best practices and its ability to overcome ongoing challenges and changes in the healthcare industry. APL achieved the Community Initiative award as a recognition for leading programmes and initiatives that contribute significantly to community causes. The Outstanding Leaders in Asia award was presented to Christophe Piganol for demonstrating sound leadership and spearheading the company's growth and prominence. "Zuellig Pharma has demonstrated how huge corporations can spearhead sustainability through the push down effect from top management, resulting in considerable change organisationally, as well as via the ripple effect to its suppliers and consumers,” said Shanggari Balakrishnan, Chief Executive Officer, MORS Group. <picture data-fileentryid="2177487"> <source media="(max-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Medical-Devices-and-Diagnostics/Sustainability-Awards-2021/ACES-2021-Joint-Release-web-2.png"></source> <source media="(max-width:280px) and (min-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Medical-Devices-and-Diagnostics/Sustainability-Awards-2021/ACES-2021-Joint-Release-web-2.png"></source> <img alt="" data-fileentryid="2177487" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Medical-Devices-and-Diagnostics/Sustainability-Awards-2021/ACES-2021-Joint-Release-web-2.png" style="display: block;margin-left: auto;margin-right: auto;height: auto;width: 351.0px;" width="351" /> </picture> "We are honoured to have been presented with four titles at the ACES Awards. This is yet another testament to the dedication and hard work of our teams to make healthcare more accessible to the communities we serve, with our sustainability agenda as an integral part of the way we run our business. The Regional, Singapore and APL teams' efforts at organising various community and employee initiatives have made a real difference to the health of our communities, and we look forward to scaling greater heights as we continue navigating these challenging times. Congratulations to all the teams involved,” shared John Graham, Chief Executive Officer, Zuellig Pharma. We are proud to be the award recipient of this esteemed award. It is an affirmation of our corporate excellence, reputation, and capabilities that we have established locally in the past 81 years. Our strong BCP framework coupled with the resiliency in our workforce have allowed us to navigate through the challenges from COVID-19. We will continue to strengthen our service offerings and drive innovation to ensure healthcare remains accessible to the community we serve in Singapore,” commented Tan Yan Ann, Chief Executive, Zuellig Pharma Singapore. "In APL, sustainability has been embedded in our DNA. This recognition energises us to continue embedding sustainability in all that we do to build a healthier future for Indonesia. Additionally, the distinction that comes from being recognised as an outstanding leader in Asia strengthens my resolve to provide an even more conducive environment for the team to develop, and to help the community at large with a particular focus to develop the next generation of leaders who are passionate to drive innovation that makes healthcare more accessible to the Indonesian people," said Christophe Piganiol, President Director, APL. The ACES Awards will be presented at a virtual event. More information about the ACES Awards and its 2021 winners can be found here:  https://www.acesawards.com/

Zuellig Pharma partners with ACEN RES to supply 100% renewable energy to two key distribution facilities in the Philippines

Zuellig Pharma, Asia’s leading healthcare solutions company, has recently signed a new strategic partnership with ACEN Renewable Energy Solutions (ACEN RES), the retail electricity arm of ACEN, to supply 100% renewable energy to power two major distribution facilities in the Philippines – the Santa Rosa Distribution Center and Canlubang Distribution Center. With the shift to 100% renewable energy from ACEN, the Santa Rosa and Canlubang Distribution Centers combined will reduce its carbon dioxide (CO2) emissions by 10,600 tons each year, equivalent to the amount of CO2 absorbed by 92,739 trees in their lifetime (approximately 30 years). Renewable energy sources, such as wind, solar, and hydropower, are key in the fight against climate change, producing electricity without contributing to Greenhouse Gas (GHG) emissions. The company’s Santa Rosa site had earlier been certified as a Leadership in Energy and Environmental Design (LEED) facility with its use of renewable energy to support the requirements of its operations. This partnership falls under the Retail Competition and Open Access (RCOA) programme, a government initiative allowing high power-consuming end-users to choose their electricity suppliers. RCOA provides businesses such as Zuellig Pharma the opportunity to opt for renewable energy supply, solidifying their commitment to sustainability. ACEN RES provides a seamless transition to renewables of businesses without them incurring additional equipment costs or causing any power interruptions, bolstering their customers’ sustainability goals. Miguel de Jesus, chief operating officer of ACEN’s Philippine operations and head of the commercial operations group, said: "ACEN is thrilled to join forces with Zuellig Pharma, a company that shares our robust commitment to sustainability. We are proud to support Zuellig Pharma by powering their operations with clean, renewable energy." Jannette Jakosalem, market managing director, Zuellig Pharma Philippines said, “The switch to renewable energy for two key distribution facilities in the Philippines is an important milestone for us, as we work towards reducing our impact on the environment and our carbon footprint across our operations and supply chains. This is a clear testament to our dedication in combating climate change. We have a long-standing commitment to build a healthier and more sustainable future for all in Asia and will continue our efforts in making an impact on climate action.” Earlier this year, Zuellig Pharma was also awarded the platinum medal from EcoVadis, the world’s most trusted provider of business sustainability ratings, for the third consecutive year, demonstrating its leadership in carbon management. The partnership with Zuellig Pharma extends the client sectors of ACEN RES further, now covering educational institutions, industrial plants, FMCG businesses, and office buildings. It represents an important step in ACEN's mission to foster a sustainable, low-carbon future for the Philippines and the broader Southeast Asian region. ACEN RES is the retail electricity unit of ACEN, an Ayala company with the largest capacity of new renewable energy in the country. ACEN is also the only Filipino-owned energy company with significant renewable energy assets in the Asia Pacific region consisting of mostly solar and wind plants in Australia, Vietnam, Indonesia, and India. In March 2023, ACEN became the first energy company in Southeast Asia to establish a robust Net Zero roadmap, which outlines near-term and long-term emission reduction targets by 2050. This decarbonisation strategy reaffirms the company’s climate ambitions as a leader in the region’s renewable energy space.

MDI works with DSAP to support healthcare professionals

MDI has signed an MOA with the Drugstores Association of the Philippines (DSAP) to host their website and launch a product catalog page to DSAP members exclusively. Through this platform, members can access attractive deals and discounts on products and can easily apply to renew their License to Operate (LTO). “The team hopes to eventually provide e-learning courses for pharmacists and pharmacy assistants to prepare for their LTO renewal and continue to add value to the services we provide to healthcare professionals in the Philippines,” said Freddie Madregallejo, VP Commercial Solutions MDI.   <picture data-fileentryid="2252864"> <source media="(max-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Insurance-and-Corporations/MDI-works-with-DSAP-to-support-healthcare-professionals/MDI_DSAP.jpeg"></source> <source media="(max-width:280px) and (min-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Insurance-and-Corporations/MDI-works-with-DSAP-to-support-healthcare-professionals/MDI_DSAP.jpeg"></source> <img alt="" data-fileentryid="2252864" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Insurance-and-Corporations/MDI-works-with-DSAP-to-support-healthcare-professionals/MDI_DSAP.jpeg" style="display: block;margin-left: auto;margin-right: auto;" /> </picture>

Zuellig Pharma awarded EcoVadis Platinum Medal for third consecutive year and rated leader in carbon management

Singapore, 13 September 2023 <picture data-fileentryid="4459844"> <source media="(max-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-pharma-ecovadis-sustainability-2023.png?mw=300"></source> <source media="(max-width:1000px) and (min-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-pharma-ecovadis-sustainability-2023.png?mw=1000"></source> <img alt="" data-fileentryid="4459844" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-pharma-ecovadis-sustainability-2023.png" /> </picture>   Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that it has achieved the platinum medal from <a href="https://ecovadis.com/" target="_blank" rel="noopener noreferrer">EcoVadis</a>, the world’s most trusted provider of business sustainability ratings, for the third consecutive year. In addition to the platinum certification, EcoVadis has also rated Zuellig Pharma as a leader in carbon management, which demonstrates its best-in-class greenhouse gas (GHG) management system and strong decarbonisation ambition with approved science-based targets. In 2023, Zuellig Pharma received an overall EcoVadis score of 82, compared to a global and Asia average of 48 and 33 points respectively. Zuellig Pharma’s work in human rights and sustainable procurement, alongside its work to reduce carbon emissions was recognised by EcoVadis in particular, placing it among the top 1% of all organisations evaluated. Since 2020, Zuellig Pharma has achieved marked improvement in its overall EcoVadis score with a total increase of 18 points, while other organisations increased their scores by 1.7 points on average in the same duration. The company has been rated consistently above the industry standard across all four pillars which include environment, labour and human rights, ethics and sustainable procurement. “This recognition by EcoVadis for the third year in a row is a testament to our long-standing commitment to sustainability, as we strive to be a world-class healthcare solutions company that builds a healthier future for Asia,” said John Graham, CEO, Zuellig Pharma. “A major contributor to the success of our sustainability efforts is ensuring year-on-year improvements across key metrics and diligently building an action plan to address the gaps identified from the previous assessment,” he added. As part of its efforts to prioritise human rights and sustainable procurement, the company launched a pilot programme “Elevating Worker Voice” in 2022, to monitor and address any labour risks in its supply chain in three markets including Malaysia, Indonesia, and the Philippines. Leveraging its partnership with The Mekong Club, a non-profit organisation specialising in detecting and eliminating modern slavery in Asia, a survey was conducted to understand the conditions faced by workers engaged by Zuellig Pharma’s suppliers. With the survey results, debriefs were conducted with suppliers, alongside collaborative efforts to address shortfalls in practices. This year, Zuellig Pharma plans to establish regional guidelines for the inclusion of worker surveys as part of supplier audits and implement the programme in sites across the region. In 2022, the company also successfully reduced its overall greenhouse gas emissions by 31% and made progress against its Science Based Targets through initiatives such as the greening of its fleets and facilities, the migration of regional services to cloud-based data centres and partnerships with suppliers to drive emission and waste reduction. The introduction of such initiatives allowed Zuellig Pharma to readjust its operations to be more energy efficient, and successfully reduced its material value chain emissions and overall carbon footprint. Earlier this year, Zuellig Pharma announced its score of “A-” for Supplier Engagement from global carbon disclosure platform <a href="https://www.cdp.net/en" target="_blank" rel="noopener noreferrer">CDP</a>, making it the first and only company worldwide in its activity group to receive this recognition. The company was also awarded a score of “B” for Climate Change. CDP is a not-for-profit charity that runs the global disclosure system for investors, companies, cities, states, and regions to manage their environmental impact. Its latest Sustainability Report can be found <a href="https://www.zuelligpharma.com/documents/d/guest/zp_sustainability2022_web-res" target="_blank" rel="noopener noreferrer">here</a>. About Zuellig Pharma Zuellig Pharma is a leading healthcare solutions company in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multi-billion dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.   Zuellig Pharma Contact Information Angelene Chong Zuellig Pharma achongam@zuelligpharma.com Sandpiper Communications zuelligpharma@sandpipercomms.com

Zuellig Pharma Singapore and GSK Establish Vaccine Distribution Hub to Improve Asia’s Access to Vaccines

Zuellig Pharma, one of the largest healthcare services groups in Asia, today announced that it has entered into an agreement with global biopharma company, GSK, to help set up its first vaccine distribution hub in the region. The vaccine distribution hub will be headquartered in Singapore, serving 13 markets in Asia-Pacific (APAC).     <picture data-fileentryid="4181113"> <source media="(max-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-Singapore-and-GSK-Establish-Vaccine-Distribution-Hub/zuelligpharma_newsinsights-GSK-Vaccine-Hub-01.jpg"></source> <source media="(max-width:1000px) and (min-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-Singapore-and-GSK-Establish-Vaccine-Distribution-Hub/zuelligpharma_newsinsights-GSK-Vaccine-Hub-01.jpg"></source> <img alt="" data-fileentryid="4181113" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-Singapore-and-GSK-Establish-Vaccine-Distribution-Hub/zuelligpharma_newsinsights-GSK-Vaccine-Hub-01.jpg" /> </picture>   Under the partnership, Zuellig Pharma Singapore will provide GSK with warehousing and distribution services in cold-chain management for its vaccines. The vaccine hub will also leverage Zuellig Pharma’s expertise in blockchain technology for China, one of GSK’s largest APAC markets.  The use of eZTracker, Zuellig Pharma’s end-to-end blockchain solution, will enhance the resiliency of GSK’s supply chain to enable greater traceability of its vaccines. This allows for better product visibility to address the growing challenge of counterfeit healthcare products in Asia.   The vaccine distribution hub will adopt a sea transport model to reduce its supply chain carbon footprint, resulting in reduced transportation carbon emissions by at least 30%, compared to air transport. All vaccines will also be under vigorous temperature control to safeguard their integrity and quality.  Tan Yan Ann, Chief Executive, Zuellig Pharma Singapore said: “GSK has been a long-term partner of Zuellig Pharma with a strong focus on improving patients’ access to healthcare. We are delighted to be able to support them in the management of their Asia supply chain. With each market having their own unique requirements, the strategic location of GSK’s vaccine hub will allow it to respond quickly to the changing healthcare landscape. Combining our cold chain expertise and proven blockchain solution, we look forward to building a stronger and more resilient supply chain with GSK to make healthcare more accessible in the communities we serve in the region.”   Robert Kruit, EVP Strategic Partnerships & Business Development, Zuellig Pharma said: “With the launch of GSK’s regional vaccine distribution hub, the strategic partnership between GSK and Zuellig Pharma delivers a profound, direct impact on vaccine availability in the region, while reducing the carbon footprint and setting a standard in supply chain traceability.”  GSK’s vaccines portfolio is the broadest in the biopharma industry, helping protect people from diseases such as meningitis, shingles, flu, polio, measles and many more. Two million of the company’s vaccines are administered every day, including to 40% of the world’s children who receive a GSK vaccine each year.1    David Brandt, Customer Supply Chain Lead, GSK said: “The demand for GSK’s vaccines in the APAC region is growing rapidly as GSK launches and grows supply of new vaccines. The new vaccines distribution hub in Singapore will become our vaccine supply gateway into the region.”  Saddam Huq, Director, Cold Chain & Logistics Network, GSK said: “This is a strategic project for GSK to drive growth and build synergies globally. The set-up of a regional distribution hub for vaccines is a major milestone for GSK distribution network, further strengthening our supply chain and contributing to our global ambition of net zero impact on climate by 2030. This partnership aligns with our purpose of getting ahead of disease together, aiming to positively impact the health of 2.5 billion people globally by the end of 2030.”  Reference:  <ol> <li> <a href="http://www.gsk.com/" target="_blank" rel="noopener noreferrer">www.gsk.com</a>: <a href="https://www.gsk.com/en-gb/company/purpose-strategy-and-culture/" target="_blank" rel="noopener noreferrer">Purpose, strategy and culture | GSK</a>. July 2023.  </li> </ol> For more information, please contact:  Linda Siow Manager, Marketing & Corporate Communications Zuellig Pharma Singapore <a href="mailto:LSiow@zuelligpharma.com" target="_blank" rel="noopener noreferrer">LSiow@zuelligpharma.com</a> Lucas Tan Director, Commercial & Program Management Zuellig Pharma Singapore <a href="mailto:cytan@zuelligpharma.com" target="_blank" rel="noopener noreferrer">cytan@zuelligpharma.com</a> About Zuellig Pharma   Zuellig Pharma is one of the largest healthcare services groups in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become a multi-billion dollar business covering 16 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.    Since 1939, our Singapore office has been providing world-class distribution, digital and commercial services to more than 6,000 customers domestically. In 1994, we established our regional distribution centre in Singapore, operating the largest secondary repackaging centres at our GMP-certified warehouses to support more than 30 regional clients in the pharma, biotech, medical device, and diagnostics industries. For more information, please visit <a href="http://www.zuelligpharma.com/" target="_blank" rel="noopener noreferrer">www.zuelligpharma.com</a>.   About GSK  GSK is a global biopharma company with the ambition and purpose to unite science, technology and talent to get ahead of disease together. For further information, please visit <a href="http://www.gsk.com/" target="_blank" rel="noopener noreferrer">www.gsk.com</a>.

Zuellig Pharma appoints John Graham as new CEO

Zuellig Pharma announces the appointment of John Graham as its new CEO. John will run the US$13 billion business and lead the team across our 13 markets in Asia. John joined Zuellig Pharma in 2018 to oversee the development and growth of our Commercial Solutions business, spearheading the growth of its marketing, sales, business development and regulatory services. He takes over the helm from former CEO John Davison who retired at the end June 2020. <picture data-fileentryid="2217741"> <source media="(max-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-appoints-John-Graham-as-new-CEO/JohnGraham_website.jpg"></source> <source media="(max-width:280px) and (min-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-appoints-John-Graham-as-new-CEO/JohnGraham_website.jpg"></source> <img alt="" data-fileentryid="2217741" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-appoints-John-Graham-as-new-CEO/JohnGraham_website.jpg" style="display: block;margin-left: auto;margin-right: auto;" /> </picture> John has over three decades of industry experience in biotech, pharmaceuticals, strategy consulting and healthcare investment banking across Europe, Asia, Latin America and the United States. He previously held various senior global leadership positions at Aventis, Genzyme and Ernst & Young, as well as the role of CEO at Menarini Asia-Pacific based in Singapore, where he established the company’s Asia-Pacific commercial footprint. “John brings with him a strong track record of strategic and operational leadership through the various global roles he has held. In his time with Zuellig Pharma, John has also driven unparalleled success in the Commercial Solutions business. We look forward to working closely with him to continue to transform the organisation and execute our exciting growth plans,” said Patrick Davies, Chairman of Zuellig Pharma. “Over the next few years, my goal is to transform Zuellig Pharma into a major integrated healthcare business that is indispensable to industry stakeholders and has a major impact on society. Together, we will continue to pursue our mission to make healthcare more accessible through providing world-class, innovative solutions to our partners and customers in distribution, commercial and digital technology,” said John. John assumed his new role on 1 July this year and is based in our headquarters in Singapore.

Zuellig Pharma partners with Luye Pharma to distribute and market Seroquel® and Seroquel XR® in Hong Kong

Zuellig Pharma enters a partnership agreement with Luye Pharma Group, an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The partnership will give Zuellig Pharma exclusive distribution and marketing rights to the central nervous system (CNS) drugs Seroquel® (quetiapine fumarate, immediate release) and Seroquel XR® (extended release formulation) in Hong Kong. <picture data-fileentryid="2218066"> <source media="(max-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-partners-with-Luye-Pharma/Luye_Pharma_Partnership.jpg"></source> <source media="(max-width:280px) and (min-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-partners-with-Luye-Pharma/Luye_Pharma_Partnership.jpg"></source> <img alt="" data-fileentryid="2218066" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-partners-with-Luye-Pharma/Luye_Pharma_Partnership.jpg" style="display: block;margin-left: auto;margin-right: auto;" /> </picture> An online signing ceremony was held in end May as part of a mental health awareness initiative “We Care About Mental Health”, marking the start of the new partnerships. Mental illnesses such as schizophrenia, bipolar disorder, depression, and anxiety place a considerable burden on global public health and the global economy. Aside from causing a serious negative social and emotional impact to sufferers and their loved ones, they also place a huge financial strain on society. With quetiapine recommended as the preferred treatment for schizophrenia and bipolar disorder by authorized guidelines on diagnosis and treatment, the new distribution and marketing partnerships come as good news for both patients and the public. “Zuellig Pharma has a comprehensive commercial platform as well as a wealth of knowledge and experience in CNS therapeutics in the Hong Kong market. The current pandemic has negatively affected many people’s mental health and created new barriers for those already suffering with this condition. We look forward to working closely with Luye Pharma on this timely partnership which is also very much in line with our overall mission to make healthcare more accessible in the region,” said Andi Umbricht, Chief Executive Zuellig Pharma Hong Kong. As part of the “We Care About Mental Health” initiative, Zuellig Pharma together with Luye Pharma has committed to organising a series of online and offline lectures hosted by expert key opinion leaders in the field of mental health, helping to educate the public and further raise awareness of matters related to mental illness. “Mental health is a serious global public health challenge that requires a sustained and united response from us all”, said Andy Siow, APAC Regional Director of Luye Pharma International. “By partnering with outstanding organizations in the region, we are confident that the ‘We Care About Mental Health’ initiative will help to increase understanding and awareness of mental health issues. It will also provide insights on the available treatment options and emphasize how important it is for sufferers to seek treatment.”

Interpharma Investments Limited appoints Alfonso “Chito” Zulueta as Non-Executive Chairman

Interpharma Investments Limited, holding company of leading healthcare services provider Zuellig Pharma, today announced the appointment of Mr. Alfonso “Chito” Zulueta as Non-Executive Chairman of its Board. Effective 1 June 2023, Mr. Zulueta succeeds Mr. Patrick Davies, who stepped down after serving as Non-Executive Chairman for four years. Mr. Zulueta joins Interpharma Investments Limited with more than three decades of experience with Eli Lilly and Company, where he was most recently President of Lilly International, and an Executive Committee member and Corporate Officer prior to his retirement in 2021. He has a strong track record in the pharmaceutical industry and extensive experience on corporate boards and industry associations. During his career with Eli Lilly and Company, he held both regional, U.S. and global roles across various functional areas including sales, marketing, product and business development, operations, and general management. Mr. Zulueta said, “Zuellig Pharma plays a unique role in the healthcare landscape in Asia, as an innovative partner in many areas across distribution and commercialisation solutions. With its rich, proven legacy and a spirit of resilience, entrepreneurship and depth, the company is well-placed for an exciting future. Patrick has been exceptional in helping steer the business through a solid period of growth. I look forward to continuing his legacy and contributing to the company’s strategy to help achieve its mission of making healthcare more accessible in Asia.” Under Mr. Davies’ leadership, Zuellig Pharma overcame a period of uncertainty and significant challenges brought about by the pandemic, including major disruptions to supply chains and pressures on healthcare systems worldwide. Mr. Davies steered the company through an important business transformation, cementing its position as an indispensable partner to the company’s key stakeholders and the communities it serves in Asia. Mr. Davies said, “The company’s success in weathering massive challenges over the past four years is a true testament of our capabilities, collective resilience and commitment towards building a healthier future for Asia. It brings me great pride to have been part of this journey and I look forward to seeing Zuellig Pharma scale greater heights in the years to come.” Interpharma Investments Limited expresses its sincerest gratitude to Mr. Davies for his valuable contribution to the Board during his four-year term and extends its warmest welcome to Mr. Zulueta. About Zuellig Pharma Zuellig Pharma (a subsidiary of Interpharma Investments Limited) is one of the largest healthcare services groups in Asia and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become an over US$15 billion business covering 16 markets with over 13,000 employees. Our people serve over 350,000 medical facilities and work with over 500 clients, including the top 20 pharmaceutical companies in the world.   Zuellig Pharma Contact Information Angelene Chong Zuellig Pharma achongam@zuelligpharma.com Sandpiper Communications zuelligpharma@sandpipercomms.com   Singapore, May 5, 2023

Zuellig Pharma recognised with a score of “A-” on CDP supplier engagement in industry first

Zuellig Pharma, one of the largest healthcare services groups in Asia, has announced its score of “A-” for Supplier Engagement from global carbon disclosure platform <a href="https://www.cdp.net/en">CDP</a>, making it the first and only company worldwide in its activity group to receive this recognition. This comes on the back of scoring “B” on CDP Climate Change earlier in the year. Zuellig Pharma first participated in this voluntary disclosure in 2021 and has improved their Climate Change score from “C” to “B”, and their Supplier Engagement score from “B” to “A-“ within a year. Their improved scores set them well above the global, Asia and industry averages and is a testament to their long-standing commitment to sustainability and driving climate action across the value chain.  CDP is a not-for-profit charity that runs the global disclosure system for investors, companies, cities, states and regions to manage their environmental impact.  “These ratings affirm our decarbonisation efforts in an industry where 70% of greenhouse gas emissions sit within the value chain. We are proud to receive recognition and are grateful to our suppliers for their commitment to sustainable business, which has enabled us to navigate the complexity of coordinating these efforts in an operationally diverse environment. We will continue working closely with our clients, customers and suppliers to drive our sustainability agenda and make a positive impact on the communities we serve,” said John Graham, CEO, Zuellig Pharma. <img alt="" height="538" width="1020" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Healthcare-Providers/Zuellig-Pharma-recognised-with-a-score-of-A--on-CDP-supplier/zuellig-pharma-news-insights-cdp-inner-image.png" /> Active engagement with suppliers to reduce carbon footprint Zuellig Pharma is the first and only company worldwide in their activity group (Road Transport) to make it to the A-list for CDP’s Supplier Engagement Rating (SER). The SER acknowledges that purchasing organisations have the potential to incentivise significant environmental changes in their supply chain through supplier engagement best practices. A significant portion of Zuellig Pharma’s efforts to reduce greenhouse gas (GHG) emissions focuses on Scope 3 emissions through procurement policies. The company incorporates sustainability criteria within its supplier selection processes and contracts and prioritises working with suppliers that demonstrate commitment to reducing their carbon footprint. Suppliers are required to report the carbon impact of activities, and the company’s largest suppliers have environmental targets that Zuellig Pharma maps against its own carbon reduction targets.  Sustainability initiatives with suppliers to reduce Scope 3 emissions include the use of biofuel and newer generation engines, driver training and monitoring to promote emission-reducing driving habits, innovative insulation in cold trucks to reduce the use of aircon blowers, aerodynamic improvement to achieve fuel savings, and constant refinement of asset utilisation rates and routes. These efforts are tracked and assessed on the IntegrityNext platform, which provides insights on suppliers' sustainability practices and enables Zuellig Pharma to flag improvement areas and mitigate issues through ongoing dialogue and education. In addition, Zuellig Pharma runs Sustainability Development Programmes to drive concrete and time-bound actions to improve sustainability performance. It also works with suppliers on one-off sustainability initiatives, such as co-developing the use of solar panels to power refrigeration units in delivery vehicles in Malaysia and launching an electric-powered fleet in South Korea to reduce its carbon footprint and increase fuel efficiency. Organisation-wide commitment to reducing greenhouse gases recognised by CDP The score of “B” on Climate Change awarded by CDP for 2022 recognises Zuellig Pharma’s commitment to reducing absolute scope 1 and 2 GHG emissions by 42% as well as a 25% reduction in absolute scope 3 GHG emissions by 2030, in addition of its goal to be carbon neutral in its own operations by that year. These targets have also been validated and approved by the Science-Based Targets initiative (SBTi). The company has gained a comprehensive view of its total direct, downstream and upstream GHG and identified opportunities for emissions reduction by screening all Scope 3 categories listed by the GHG Protocol to identify those relevant to its activities. This has enabled it to initiate actions such as: <ul> <li> Reducing energy use from IT infrastructure by moving most of its regional services from on-premises hosting to cloud-based Microsoft Azure data centres, achieving greater energy efficiency of up to 93% and greater carbon efficiency of up to 98%.  </li> <li> Rolling out solar panel installation starting in Taiwan and Vietnam with installation planned for Singapore, Thailand, and Cambodia in 2023. This has so far generated 5.4M kWh, covering 5% of electricity needs. </li> <li> Switching to electric vehicles – The company is actively moving towards greener transport fleets in selected markets. By 2030, internal combustion engine (ICE) delivery vehicles will be phased out in Singapore, while Korea will use electric vehicles for all short-distance deliveries. </li> </ul> Apart from CDP ratings, Zuellig Pharma’s sustainability efforts have also been recognised with the EcoVadis Platinum certification for two years running, placing the company at the top 1% of all assessed companies worldwide and ranking it #1 globally in their industry amongst 2,800 logistics leaders. Its latest Sustainability Report can be found <a href="https://www.zuelligpharma.com/documents/d/guest/zp_sustainability2022_web-res">here</a>.    About Zuellig Pharma Zuellig Pharma is one of the largest healthcare services groups in Asia, and our mission is to make healthcare more accessible to the communities we serve. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started a hundred years ago and has grown to become an over US$15 billion business covering 16 markets with over 13,000 employees. Our people serve over 350,000 medical facilities and work with over 500 clients, including the top 20 pharmaceutical companies in the world.    Zuellig Pharma Contact Information  Angelene Chong  Zuellig Pharma  <a href="mailto:achongam@zuelligpharma.com">achongam@zuelligpharma.com</a>   Sandpiper Communications  <a href="mailto:zuelligpharma@sandpipercomms.com">zuelligpharma@sandpipercomms.com</a>  Singapore, April 27, 2023

COVID-19 Vaccines Clinical Trial Environment

The World Health Organization officially declared the coronavirus outbreak a pandemic in March 2020. By June 2021, 170 vaccine candidates for COVID-19 had been developed. Of these, 90 were being tested in human clinical trials, 30% had reached Phase 3 and selected vaccines had been authorised for emergency use. There are at least 440 clinical trials with mRNA candidates and at least 140 for viral vectors. In providing a wide range of services and fostering cooperative partnerships across all domains of healthcare, we seek to leverage the power of collaboration in service of healthcare solutions. We also continue to pursue partnerships with forward-thinking industry leaders. Together we combine our unique resources to create results that matter. Working with partners across a broad range of healthcare domains is our priority at Zuellig Pharma.   <picture data-fileentryid="1978626"> <source media="(max-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/COVID-19-Vaccines-Clinical-Trial-Environment/blog2Xph01.jpg"></source> <source media="(max-width:1000px) and (min-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/COVID-19-Vaccines-Clinical-Trial-Environment/blog2Xph01.jpg"></source> <img alt="" data-fileentryid="1978626" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/COVID-19-Vaccines-Clinical-Trial-Environment/blog2Xph01.jpg" /> </picture>   Our Roles & Responsibilities in Temperature Management Zuellig Pharma has established capabilities in providing world-class temperature-controlled ecosystems consisting of warehousing facilities, packaging and temperature monitoring systems, and delivery infrastructure. We pride ourselves on our commitment to quality and maintaining product integrity, through practices that meet international regulatory standards. We are certified compliant with Good Storage and Distribution Practice, GDP and GMP (for secondary repackaging) by the British Standard Institution and have passed multiple annual Good Practice audits by clients. To ensure cold chain integrity, Zuellig Pharma has invested significantly in new solutions to mitigate the risk of temperature excursions. These range from sophisticated temperature management systems in warehouses, to packaging such as the Zuellig Pharma eZCooler, which keeps drugs at the right temperatures for up to five days. This ensures last mile integrity in Southeast Asia where the climate is humid and transportation infrastructure is limited outside of capital cities. With its phase-change coolants and vacuum insulated panels, the eZCooler provides extended retention capability and has a lifetime of four years. It is also 100% recyclable. In addition, we use temperature monitors, sensors and track and trace systems along the entire supply chain to maintain the integrity of the drugs we transport every day. Reports are generated at the end of a delivery to confirm no temperature excursions have occurred. Soon, real-time monitoring will pair with the ability to provide instant alerts if temperature trends deviate beyond the safe range so that immediate remedial action can be taken.

Zuellig Pharma brings logistics expertise to support the Thai government in distribution of one million doses of COVID -19 vaccine Moderna donated by the US government for Thai people

Zuellig Pharma announced its commitment to support the Thai Government, through the Department of Disease Control, Ministry of Public Health. Zuellig Pharma will provide warehousing and transportation services without charge for one million doses of COVID-19 Vaccine Moderna donated by the US Government, as part of its ongoing support to the country’s key mission in achieving herd immunity. <picture data-fileentryid="2174664"> <img alt="" height="156" width="280" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Healthcare-Providers/Zuellig-Pharma-brings-logistics-expertise-to-support-the-Thai-government/ThaiGovt_Donation_Moderna.jpeg" /> Dr. Opart Karnkawinpong, Director-General of the Department of Disease Control, Ministry of Public Health said “The donation of Covid-19 Vaccine Moderna from the US Government to the Thai Government through the Ministry of Foreign Affairs will be used to serve the public’s beneficial use with the plan to allocate the vaccines to the outbreak areas of Coronavirus 2019. The donated vaccine must not be exploited for other purposes such as re-selling. Furthermore, delivery of the vaccines across the country will require to be temperature-controlled throughout transportation process to ensure its quality being maintained and to support herd immunity building for both Thais and foreigners living in Thailand. With this specific controlled condition, it requires specialty in this area. We are pleased to receive exceptional support from Zuellig Pharma in managing logistics process of the donated vaccines for us as a part of the nation’s mission.” Ms. Pucknalin Bulakul, Chief Executive of Zuellig Pharma Thailand said,  </picture> “We are very honoured and proud to be a part of the supports to the government agencies in serving public benefits. We are pleased to bring our logistics capabilities and expertise in the storage and delivery of the vaccines and to maintain the quality of the donated vaccine until delivery at the destination without charge. This support is aligned with our company’s mission in making healthcare more accessible. We are ready to collaborate with all sectors to achieve the country’s COVID-19 vaccination plan in building herd immunity including responding to the country's re-opening policy so as to drive the economy with balance and efficiency.” About Department of Disease Control Department of Disease Control, Ministry of Public Health is one of the government agencies, which brings significance to the advancement of public health. We aim to become a leading organization in academics and technology for disease control and prevention both locally and internationally. The Department of Disease Control also promotes collaborative efforts among local and international networks for the development of experts, knowledge and information sharing, tools, surveillance laws, disease control and prevention, health hazards, as well as specific services with the global standard.

ZP Therapeutics ready to deliver the first shipment of COVID-19 vaccine Moderna to increase vaccine access in Thailand

The Government Pharmaceutical Organisation, represented by Ms. Sirikul Matevelungsun (third from left), Deputy Managing Director, together with The Private Hospital Association, represented by Dr. Paiboon Eksaengsri (far right), Secretary-General, received the first 560,000 doses of COVID-19 Vaccine Moderna from Zuellig Pharma, led by Ms. Sunaiyanaa Kidkasetpaisal (second from left), General Manager, ZP Therapeutics, and Ms. Pucknalin Bulakul (far left), Chief Executive, Zuellig Pharma Thailand, at Suvarnabhumi Airport. The shipment was delivered by Lufthansa Airways, flights LH 772. ZP Therapeutics is ready to deliver the first shipment of 560,000 doses of COVID-19 Vaccine Moderna to the Government Pharmaceutical Organisation (GPO) for distribution to the Private Hospital Association in an effort to increase access to alternative vaccines for the people of Thailand. Ms. Sunaiyanaa Kidkasetpaisal, General Manager at ZP Therapeutics, Zuellig Pharma Thailand, stated, "The company is pleased to announce that we are ready to deliver the first batch of 560,000 doses of COVID-19 Vaccine Moderna as previously stated. The remaining of the 1.9 million doses will continue to be delivered until the end of 2021 as informed by Moderna. The other 6.8 million doses are expected to be handed over in the first quarter of 2022. ZP Therapeutics draws upon our unparalleled commercialisation capabilities, expertise, and experience to support the Thai government and private healthcare institutions in advancing national efforts for COVID-19 vaccination programmes." Ms. Pucknalin Bulakul, Chief Executive at Zuellig Pharma Thailand, said, "We will draw upon our capabilities and expertise in storage and distribution of pharmaceutical products and vaccines, leveraging on our cutting-edge technologies in supply chain and cold-chain logistics. This is to ensure the quality of the COVID-19 Vaccine Moderna, which needs to be stored at the controlled temperature of -20°C during transportation to hospitals and vaccination sites. We put our efforts to accelerate the vaccine distribution to various areas across the country." Ms. Sirikul Matevelungsun, Deputy Managing Director, Government Pharmaceutical Organisation, said, "The Government Pharmaceutical Organisation is appointed as the government agency for the procurement of alternative vaccines to increase vaccine access for Thai people. We would like to thank the Private Hospital Association and Zuellig Pharma for their support in pushing forward for the availability of the vaccines. After the vaccines undergo all the necessary quality inspection and testing, Zuellig Pharma will then distribute the vaccines to private hospitals according to the portion of the pre-ordered quota." "Since the beginning of the COVID-19 pandemic, the Government Pharmaceutical Organisation has committed to performing all relevant missions in securing the supply and procurement of medicines, vaccines, medical devices and protection equipment. We support the country’s public health system to reduce infection and mortality rates, in an effort to drive the economy forward,” said the Deputy Managing Director. Dr. Chalerm Harnphanich, Chairman of The Private Hospital Association, added, "The Association had previously notified each hospital on the preparation of vaccination services for those who have made the bookings. We will continue working closely with the Government Pharmaceutical Organisation and ZP Therapeutics to follow up on the next batch of delivery to ensure that we bring adequate supply of the vaccines to the people of Thailand as soon as possible. The COVID-19 Vaccine Moderna is a highly sought-after alternative vaccine. According to clinical trials, two-dose primary series of the vaccine showed up to 94% efficacy in preventing symptomatic COVID-19 infection in adults. Results from real-world effectiveness demonstrated the vaccine reduces risk of infection by 91% for fully vaccinated people, with recent studies showing the vaccine to remain effective against the Delta variant."

Zuellig Pharma and GW Pharmaceuticals sign a partnership agreement in Taiwan

Zuellig Pharma announced a new partnership with GW Pharmaceuticals (GW) to support access to cannabis-based medicines in Taiwan. GW, part of Jazz Pharmaceuticals plc, is a world leader in discovering, developing, and delivering regulatory approved cannabis-based medicines. As part of GW’s commitment to bringing its medicines to patients and clinicians in Taiwan, it has chosen Zuellig Pharma Taiwan to support appropriate access to GW’s medicines given Zuellig Pharma’s position as the leading medical solutions provider with an end-to-end medical service value chain. From clinical trials, distribution, pharmaceutical commercialisation to patient care services, Zuellig Pharma Taiwan has excellent coverage in pharmaceutical channels, especially in GP and drug stores. John Chou, Managing Director of Zuellig Pharma Taiwan said, “We are honored to have the opportunity to work with GW Pharmaceuticals when the company decided to enter Asia’s markets. Our company has been present in Taiwan for more than 30 years and has been the business partner of choice for biotechnology companies seeking business expansion in the region. Through this partnership, we hope to make new and innovative therapeutic drugs available for Taiwanese patients, thereby fulfilling Zuellig Pharma’s mission of making healthcare more accessible in Taiwan.” Joseph Lai, General Manager of ZP Therapeutics, Zuellig Pharma Taiwan shared, “ZP Therapeutics has a deep understanding of the Taiwanese market, healthcare ecosystem and an extensive healthcare commercial team. ZP Therapeutics will continue to deepen our presence in the fields of diabetes, immunology, oncology, vaccines and rare diseases. “Formally establishing our partnership with Zuellig Pharma in Taiwan underscores our long-term commitment to supporting Taiwanese patients and physicians and furthers GW’s mission to bring innovative medicines to patients with high unmet need” said Chris Tovey, Jazz’s Chief Operating Officer. “Our drive to find solutions for complex medical problems has resulted in the regulatory approval of world-first treatments in a new frontier of medicine.” <picture data-fileentryid="2174785"> <img alt="" height="165" width="280" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-and-GW-Pharmaceuticals-sign-a-partnership-agreement-in-Taiwan/GWPharma_ZPTW2021_web.png" /> About GW Pharma Limited GW Pharmaceuticals (GW), a subsidiary of Jazz Pharmaceuticals plc, has established a world-leading position in cannabinoid science and medicine. Founded over two decades ago in response to significant unmet patient need, patients remain our key focus and improving their quality of life, our motivation. GW’s pioneering work has led to the regulatory approval of world first, potentially life changing, cannabis-based medicines. Our continued dedication has resulted in the treatment of thousands of patients with our medicines in the UK and around the world. In 2021, GW received the Queens Award for Enterprise in Innovation in recognition of its innovative and ground-breaking work in developing prescription cannabis-based medicines. GW was acquired by Jazz Pharmaceuticals in May 2021. About Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.</picture>

Updates on the first shipment of COVID-19 vaccine Moderna to Thailand

ZP Therapeutics, a division of Zuellig Pharma and the official partner of Moderna in Thailand, confirms that the first shipment of 560,000 doses of COVID-19 Vaccine Moderna will arrive in Thailand within 5 November 2021, based on the latest schedule provided by Moderna. We had already put into place all measures to pick up and deliver the batch to Thailand as soon as they are made available to us. The company is also on track per the confirmation provided by Moderna to deliver the remaining of the 1.9 million doses of COVID-19 Vaccine Moderna to Thailand within the fourth quarter of 2021. The other 6.8 million doses are still expected to be delivered in the first quarter of 2022. <picture data-fileentryid="3633940"> <source media="(max-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Updates-on-the-first-shipment-of-COVID-19-vaccine-Moderna-to-Thailand/zpt_thailand_moderna.jpeg"></source> <source media="(max-width:1000px) and (min-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Updates-on-the-first-shipment-of-COVID-19-vaccine-Moderna-to-Thailand/zpt_thailand_moderna.jpeg"></source> <img alt="ZP Therapeutics delivering Moderna vaccine in Thailand" data-fileentryid="3633940" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Updates-on-the-first-shipment-of-COVID-19-vaccine-Moderna-to-Thailand/zpt_thailand_moderna.jpeg" /> </picture> To ensure that we bring adequate and consistent supply of vaccines to the people of Thailand, ZP Therapeutics has submitted the documents to register Moderna’s US manufacturing site with Thailand’s Food and Drug Administration (FDA) on top of the currently approved manufacturing site on 20 October 2021. As of now, the documents are being considered by the FDA. We are working closely with the FDA for a smooth registration process and will provide further updates in due course. ZP Therapeutics remains committed to supporting the government of Thailand in achieving their mass COVID-19 vaccination goals by providing COVID-19 Vaccine Moderna to the people of Thailand.

Making good mental health a reality

By Jen Garcia, VP Human Resources & Corporate Communications Technology like smartphones, laptops and smartwatches have blurred the lines between work and personal time even before the COVID-19 pandemic hit us almost two years ago. I remember a time when my evening jogs or weekend bike rides were refreshing bursts of me-time without the distraction of work. Family vacations were also once considered sacred. But many of us, myself included, now feel guilty for not bringing our work laptops with us on vacations. Perhaps, because I think I am expected to stay on top of my work or at the very least, stay connected even while I rest and recuperate. We compose our out-of-office notification messages in a manner that grants others permission to reach us through various channels. When the smartwatch, which I’ve grown too dependent on, vibrates every time I receive a text message, an email or Teams chat, I can’t bring myself to ignore it. I feel bad when I can’t respond immediately. We have generally made a smooth transition from a face-to-face work environment to virtual and work-from-home arrangements because of the pandemic. This new normal has largely not had any adverse effect on employee productivity and may have even improved the output of work. Unfortunately, our productivity gains have inadvertently led to significant losses in terms of mental health, family time, and personal relationships. It is an issue that many companies are aware of, and HR teams have responded to this by providing initiatives in an attempt to relieve the pressures of work and make employees feel better. Relaxation packs, wellness speakers, guided mindful activities are just some of the laudable and well-intended activities that I’ve come across. However, these are solutions that temporarily alleviate some symptoms but do not address the root cause of these stressors. At Zuellig Pharma, we encourage employees to be mindful of keeping a healthy work life balance. While there is no one-size-fits-all formula for this, leaders are encouraged to carefully prioritize work and ensure effective resource allocation to prevent frustration and burnout. Healthy interpersonal relationships are likewise encouraged as next to family and friend, colleagues at work are probably are closest support systems. When these fail, employees are provided the option to seek professional help to manage life and work stressors before these cause a negative impact on their lives. In the Philippines, health benefits cover reimbursement for therapy and counselling sessions, while in Hong Kong and Singapore, we provide hotlines for people to call when they feel the need to speak with someone about work and personal issues. In the future, we will also explore having our Zuellig Pharma managers trained in psychological first aid to better support our employees on a day-to-day basis. <picture data-fileentryid="2174841"> <img alt="" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Consumer-Health/Making-good-mental-health-a-reality/ZP_WorldMentalHealthDay_2021_2_web.png?h=156&w=280" style="display: block;margin-left: auto;margin-right: auto;" /> </picture> To commemorate World Mental Health Day on 10 October, I would like to offer three simple steps to manage stressors and ensure a good work-life balance:   <ol> <li>Ask for help When experiencing difficulties because of excessive workload, tight deadlines, a lack of resources to get the job done or even domestic concerns hindering you from doing your best at work, ask for help. Sometimes, simply talking about something can point the way towards a solution. Remember that you are not alone!  </li> <li>Plan your day to incorporate rest time Taking the time to rest does not mean you are being unproductive or slacking off. It is probably unrealistic to dream about a grand two-week vacation completely detached from work. But turning your computer off by a certain time is certainly doable. Silencing your phone for a family dinner will most likely not lead to a significant business loss. As for me, I will leave my smartwatch behind the next time I go on my evening jog or weekend bike ride to enjoy the scenery.  </li> <li>Commit to check-in on each other We should not be too caught up in our lives to not notice when our workmates or our friends are having a difficult time. If we hear frustration in their voices, see sadness and worry in their eyes, notice exhaustion in their posture and their gait – let us take the initiative to check in on them. But when we ask “How are you?”, let’s not settle with hearing the usual “I’m okay”. Be prepared to stop, look our colleagues or friends in the eye and ask, “No really, – how are you?” with a sincere intention to listen and to care. Whether it is the three handles above or other ways that help us to keep our minds healthy, I hope these efforts of self-care and care for others go towards making mental health care a reality for our generation and future ones.</li> </ol>

Zuellig Pharma receives EcoVadis Platinum Sustainability rating for the year 2021

Zuellig Pharma has been awarded the Platinum Medal 2021 by sustainability ratings specialist <a href="https://ecovadis.com/" target="_blank" rel="noopener noreferrer">EcoVadis</a>. The award is the highest accolade to be awarded to a company for its sustainability efforts and positions Zuellig Pharma in the top 1% of all assessed companies worldwide. This award also places the company in a select group of winners including 150 global multinational companies, some belonging to Fortune 500 companies. Zuellig Pharma had steadily progressed from being awarded a Silver Medal in 2020 to a Gold Medal earlier in 2021, before clinching this latest Platinum Medal. The medal was awarded after a rigorous assessment of Zuellig Pharma’s sustainability programme, covering 21 sustainability criteria across four themes, including Environment, Labour and Human Rights, Ethics and Sustainable Procurement. The company’s sustainability programme was evaluated on its policies, actions put in place to support objectives and targets, as well as results that were generated from the programme. "Sustainability is deeply embedded in the way we run our organisation and guides us in driving impact for our key stakeholders. This award, coming from the world's most trusted business sustainability rating, is a major milestone in our Sustainability journey and represents the great progress we have been making in building a healthier future for Asia. We could not have achieved this without the tireless dedication and support of every single employee in our team, and our clients, customers, suppliers and partners,” said John Graham, CEO, Zuellig Pharma. Zuellig Pharma is committed to the United Nations Global Compact and published its first ever <a href="https://www.zuelligpharma.com/about-us/sustainability/sustainability-gri-reports" target="_blank" rel="noopener noreferrer">GRI-aligned Sustainability</a> Report in 2020. The organisation is holding its second Sustainability Month this year which includes a month-worth of activities to rally stakeholders around its Sustainability Agenda. EcoVadis is a trusted provider of business sustainability ratings, creating a global network of more than 75,000 rated companies. The company’s sustainability scorecards provide detailed insight into environmental, social and ethical risks across more than 200 purchasing categories and over 160 countries.

Chulabhorn Royal Academy signs agreement with Zuellig Pharma to purchase eight million doses of COVID-19 vaccine Moderna

The Chulabhorn Royal Academy (CRA) announced an official agreement with ZP Therapeutics, a division of Zuellig Pharma on the supply and distribution of eight million doses of the COVID-19 Vaccine Moderna in Thailand. Aimed for use as prime and booster vaccination, if and when approved, a portion of the vaccines will be allocated to people from vulnerable and underprivileged groups. The first shipment of the vaccines is anticipated to be delivered during the first quarter of 2022. Professor Nithi Mahanonda, MD., Secretary-General of Chulabhorn Royal Academy, said, "The Chulabhorn Royal Academy has been working closely with the government and related private organizations to combat the ongoing pandemic by offering more vaccine options to the general public, business corporations, vulnerable groups and underprivileged people amidst the emergency situation. The Academy also focuses on conducting research studies of COVID-19 vaccines in Thailand and plans to concurrently conduct systematic research to confirm the immune response results in the country's environment, starting from the end of this year.” "This collaboration with Zuellig Pharma is an important mission that marks our continued efforts to ensure the inclusivity of vaccine distribution and to drive Thailand's economic recovery. Guided by the aspiration of Professor Dr. Her Royal Highness Princess Chulabhorn Krom Phra Srisavangavadhana, Chancellor of Chulabhorn Royal Academy, we remain committed to equitably providing the public with quality medical services for all,” added Professor Nithi. Sunaiyanaa Kidkasetpaisal, General Manager, ZP Therapeutics, Zuellig Pharma Thailand, said, "We are honoured to be collaborating with the Chulabhorn Royal Academy in increasing access to the COVID-19 Vaccine Moderna. As the official partner of Moderna in Thailand, ZP Therapeutics draws upon our unparalleled commercialisation capabilities, expertise, and experience to support Thailand's vaccination programmes. In particular, being future-ready to provide protection against new variants of concern with supportive clinical data and when approved by the local authorities." Similar to its previous COVID-19 vaccine procurements, the Chulabhorn Royal Academy will also work with the Ministry of Public Health in allocating a portion of the COVID-19 Vaccine Moderna to interested business corporations. The central nationwide vaccine price, inclusive of vaccination insurance, will be announced in due course. <img alt="" height="156" width="280" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Healthcare-Providers/Chulabhorn-Royal-Academy-signs-agreement-with-Zuellig-Pharma-to-purchase-eight-million-doses/CA_ZPT_web.jpg" style="display: block;margin-left: auto;margin-right: auto;" /> Zuellig Pharma provides world-class distribution, digital and commercial services to over 350,000 medical facilities and its more than 1,000 clients, including the top 20 pharmaceutical companies globally. With over 70 years of experience in Thailand, the company is equipped with global standard warehouses and cold chain capacity of more than 40,000 sqm, and distributes more than 80% of the nation's vaccines today. About Chulabhorn Royal Academy Chulabhorn Royal Academy adheres to the philosophy of "Be Excellent for Lives". One of the Academy's missions is to promote our institution to be organizational excellence in grooming students and personnel in the fields of science and medicine so that they are able to think critically, generate new knowledge, conduct related research, and apply the knowledge to the real situations. Furthermore, with ethics and humanitarian in mind, they are able to provide the public with quality medical services for all. At the institute, unity and willingness to contribute for the cause of the institute and the country are also observed. Their selfless devotion and acquired characters will eventually benefit all Thai citizens. These core values - providing knowledge and fostering morals - are upheld by the institute. Both are indispensable aspects of such an institute par excellence as the Chulabhorn Royal Academy.

Thailand's food and drug administration expands authorisation of COVID -19 vaccine Moderna for use in adolescents 12 to 17 years old

ZP Therapeutics, a division of Zuellig Pharma today announced that Thailand Food and Drug Administration (FDA) has expanded the authorisation of the COVID-19 Vaccine Moderna for use in adolescents aged 12 to 17 years old. The vaccination regimen is the same as that for adults – two doses of the vaccine to be administered 28 days apart. "The approval of COVID-19 Vaccine Moderna for use in adolescents expands the vaccine arsenal that Thailand has to combat the pandemic. We are grateful that the Food and Drug Administration has authorised the use of the COVID-19 Vaccine Moderna for adolescents so that they can be offered protection against the coronavirus, especially in light of the highly contagious Delta variant. We are working tirelessly to support Thailand's mass vaccination efforts. The more people we help to get vaccinated against the virus, the quicker we will reach herd immunity, and the faster we will be able to transition towards normalcy. We are very proud to have a role to play in this process," said Ms. Sunaiyanaa Kidkasetpaisal, General Manager, ZP Therapeutics, Zuellig Pharma Thailand. <picture data-fileentryid="2177456"> <source media="(max-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Thailand-food-and-drug-administration-expands-authorisation-of-COVID--19-vaccine-Moderna/TH_adolescent_indication_web.png"></source> <source media="(max-width:280px) and (min-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Thailand-food-and-drug-administration-expands-authorisation-of-COVID--19-vaccine-Moderna/TH_adolescent_indication_web.png"></source> <img alt="" data-fileentryid="2177456" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Thailand-food-and-drug-administration-expands-authorisation-of-COVID--19-vaccine-Moderna/TH_adolescent_indication_web.png" style="display: block;margin-left: auto;margin-right: auto;height: auto;width: 434.0px;" width="434" /> </picture> In May, Moderna announced that the Phase 2/3 TeenCOVE study of COVID-19 Vaccine Moderna in adolescents met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. Two-dose primary series of COVID-19 Vaccine Moderna showed 100% efficacy in protecting adolescents aged 12 to 17 from symptomatic infection. The vaccine was generally well tolerated with a safety and tolerability profile generally consistent with the Phase 3 COVE study in adults. Safety data continues to accrue, and the study continues to be monitored by an independent safety monitoring committee. These data are subject to change based on ongoing data collection.

Department of disease control appoints Zuellig Pharma to handle 20 million doses Pfizer-BioNTech COVID-19 vaccines in Thailand

Zuellig Pharma has been appointed by the Department of Disease Control to handle and distribute another 20 million doses of the Pfizer-BioNTech COVID-19 vaccines in Thailand. The vaccines will be stored and transported at the required temperature range of -90 degrees to -60 degrees Celsius. The team has successfully warehoused and transported 1.5 million doses of the vaccines donated to the Thai government by the United States, nationwide, in accordance with all specified standards and to the highest levels of delivery. As a result of successful delivery, the team has once again been selected by the local Department of Disease Control to continue to distribute the vaccines efficiently. <picture data-fileentryid="2174697"> <source media="(max-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Healthcare-Providers/Department-of-disease-control-appoints-Zuellig-Pharma-to-handle-20-million-doses-Pfizer-BioNTech/ZPTH_DDC_PfizerVaccines_web.jpg"></source> <source media="(max-width:280px) and (min-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Healthcare-Providers/Department-of-disease-control-appoints-Zuellig-Pharma-to-handle-20-million-doses-Pfizer-BioNTech/ZPTH_DDC_PfizerVaccines_web.jpg"></source> <img alt="" data-fileentryid="2174697" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Healthcare-Providers/Department-of-disease-control-appoints-Zuellig-Pharma-to-handle-20-million-doses-Pfizer-BioNTech/ZPTH_DDC_PfizerVaccines_web.jpg" /> </picture> Zuellig Pharma Thailand is the largest pharmaceutical cold-chain logistics provider in the country. To ensure the highest quality and integrity of the temperature-sensitive vaccines to be delivered to the Thai people, the vaccines will be safely stored in specialised freezers within the temperature range of -90 degrees and -60 degrees Celsius in accordance with the product specifications and will be transported in our innovative passive packaging solution. <picture data-fileentryid="4079559"> <source media="(max-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Healthcare-Providers/Department-of-disease-control-appoints-Zuellig-Pharma-to-handle-20-million-doses-Pfizer-BioNTech/zuellig-pharma-news-insights-moderna-pfizer-biontech-thailand-inner-image.jpg"></source> <source media="(max-width:1000px) and (min-width:300px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Healthcare-Providers/Department-of-disease-control-appoints-Zuellig-Pharma-to-handle-20-million-doses-Pfizer-BioNTech/zuellig-pharma-news-insights-moderna-pfizer-biontech-thailand-inner-image.jpg"></source> <img alt="" data-fileentryid="4079559" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Healthcare-Providers/Department-of-disease-control-appoints-Zuellig-Pharma-to-handle-20-million-doses-Pfizer-BioNTech/zuellig-pharma-news-insights-moderna-pfizer-biontech-thailand-inner-image.jpg" /> </picture> Zuellig Pharma is confident in our systems and expertise in distribution and logistics management which are specifically designed to ensure the highest quality of delivery. The team is proud to play an important part in the vaccine distribution in the COVID-19 pandemic and continuing our mission of making healthcare more accessible.

Zuellig Pharma Thailand collaborates with the department of disease control (ddc) to provide nationwide distribution services of 1.5million doses of pfizer-biontech COVID -19 mrna vaccines

Vaccines will be stored between -80°C and -60°C Zuellig Pharma Thailand has collaborated with the Department of Disease Control (DDC) Thailand to distribute 1.5million doses Pfizer-BioNTech COVID-19 mRNA vaccines nationwide. Pfizer-BioNTech COVID-19 Vaccines are required to be stored between -80°C and -60°C. Zuellig Pharma Thailand offers the largest pharmaceutical cold chain distribution facilities locally with various temperature ranges including -80°C to -60°C, -25°C to -15°C, 2°C to 8°C and 15°C to 25 °C. Our innovative eZCooler solution is also being used to ensure the temperature integrity of the vaccines during the last mile of transportation. "Zuellig Pharma is committed to leveraging our experience, expertise and our best in class cold chain solutions for distribution of vaccines, pharmaceutical and medical products to provide access to COVID-19 vaccines to the people in Thailand. We are entrusted by the DDC Thailand to distribute 1.5 million doses of Pfizer-BioNTech COVID-19 mRNA vaccines,” said Pucknalin Bulakul, Chief Executive of Zuellig Pharma Thailand. “We are proud to be a part of the vaccine distribution which will help to protect the people in Thailand from COVID-19 and achieve our mission of Making Healthcare More Accessible." <picture data-fileentryid="2177514"> <source media="(max-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-Thailand-collaborates-with-the-department-of-disease-control/ZPTH_DDC_PfizerBioNTech_web.jpg"></source> <source media="(max-width:280px) and (min-width:280px)" srcset="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-Thailand-collaborates-with-the-department-of-disease-control/ZPTH_DDC_PfizerBioNTech_web.jpg"></source> <img alt="" data-fileentryid="2177514" src="https://edge.sitecorecloud.io/zuelligphar9b34-zpcms-test-fcf9/media/Project/Corporate/News/Pharmaceutical-Companies/Zuellig-Pharma-Thailand-collaborates-with-the-department-of-disease-control/ZPTH_DDC_PfizerBioNTech_web.jpg" style="display: block;margin-left: auto;margin-right: auto;" /> </picture>

1 /0

2022

Forward-Thinking Industry Quality Leadership

We build strong quality culture in the pharmaceutical industry through agile people development, while supporting organisation Quality Assurance needs to meet strategic business goals and driving digital enablement.

2023

Quality Leadership Gives Clear Competitive Advantage

We offer transparent career pathways to make Quality Assurance a vocational choice among employees, as we attract talents who can effectively deal with the escalating complexity of compliance in the pharmaceutical industry.

2024

Value Creation through Quality Leadership

We model Quality Assurance competency as an integral part of our human capital development and establish ourselves as recognised thought leaders in the quality process, both internally and externally.

Making Healthcare More Accessible in Asia

Unlock the potential of Asia with Zuellig Pharma's unique healthcare solutions.

Opportunities

Capabilities

Opportunities

Capabilities

Opportunities

Capabilities

Opportunities

Capabilities

Opportunities

Capabilities

Opportunities

Capabilities

Opportunities

Capabilities

Opportunities

Capabilities

Opportunities

Capabilities

Opportunities

Capabilities

Opportunities

Capabilities

Opportunities

Capabilities

Opportunities

Capabilities

Opportunities

Capabilities

Opportunities

Capabilities

Solutions

Segments

Technology Solutions

eZTracker

eZRx

About Us

Sustainability

News and Insights

BA TEST 18 MARCH

Zuellig Pharma wins four awards at the Asia corporate excellence & sustainability awards 2021

Zuellig Pharma partners with ACEN RES to supply 100% renewable energy to two key distribution facilities in the Philippines

MDI works with DSAP to support healthcare professionals

Zuellig Pharma awarded EcoVadis Platinum Medal for third consecutive year and rated leader in carbon management

Zuellig Pharma Singapore and GSK Establish Vaccine Distribution Hub to Improve Asia’s Access to Vaccines

Zuellig Pharma appoints John Graham as new CEO

Zuellig Pharma partners with Luye Pharma to distribute and market Seroquel® and Seroquel XR® in Hong Kong

Interpharma Investments Limited appoints Alfonso “Chito” Zulueta as Non-Executive Chairman

Zuellig Pharma recognised with a score of “A-” on CDP supplier engagement in industry first

COVID-19 Vaccines Clinical Trial Environment

Zuellig Pharma brings logistics expertise to support the Thai government in distribution of one million doses of COVID -19 vaccine Moderna donated by the US government for Thai people

ZP Therapeutics ready to deliver the first shipment of COVID-19 vaccine Moderna to increase vaccine access in Thailand

Zuellig Pharma and GW Pharmaceuticals sign a partnership agreement in Taiwan

Updates on the first shipment of COVID-19 vaccine Moderna to Thailand

Making good mental health a reality

Zuellig Pharma receives EcoVadis Platinum Sustainability rating for the year 2021

Chulabhorn Royal Academy signs agreement with Zuellig Pharma to purchase eight million doses of COVID-19 vaccine Moderna

Thailand's food and drug administration expands authorisation of COVID -19 vaccine Moderna for use in adolescents 12 to 17 years old

Department of disease control appoints Zuellig Pharma to handle 20 million doses Pfizer-BioNTech COVID-19 vaccines in Thailand

Zuellig Pharma Thailand collaborates with the department of disease control (ddc) to provide nationwide distribution services of 1.5million doses of pfizer-biontech COVID -19 mrna vaccines

2022

2023

2024